Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 392

1.

Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.

Pietrantonio F, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE, Choi YY, Kim KM, Nankivell MG, Morano F, Wotherspoon A, Valeri N, Kook MC, An JY, Grabsch HI, Fucà G, Noh SH, Sohn TS, Kim S, Di Bartolomeo M, Cunningham D, Lee J, Cheong JH, Smyth EC.

J Clin Oncol. 2019 Sep 12:JCO1901124. doi: 10.1200/JCO.19.01124. [Epub ahead of print]

PMID:
31513484
2.

PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation.

Kim HN, Jang J, Heo YJ, Kim B, Jung H, Jang Y, Kang SY, Kim ST, Lee J, Kang WK, Kim KM.

Virchows Arch. 2019 Aug 28. doi: 10.1007/s00428-019-02653-2. [Epub ahead of print]

PMID:
31463730
3.

Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study.

Kwon D, Kim B, Shin HC, Kim EJ, Ha SY, Jang KT, Kim ST, Lee J, Kang WK, Park JO, Kim KM.

Transl Oncol. 2019 Aug 20;12(11):1488-1495. doi: 10.1016/j.tranon.2019.07.017. [Epub ahead of print]

4.

Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification.

Kim ST, Lee IK, Rom E, Sirkis R, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim KM, Yayon A, Lee J.

Am J Transl Res. 2019 Jul 15;11(7):4508-4515. eCollection 2019.

5.

Tumor genomic profiling guides metastatic gastric cancer patients to targeted treatment: The VIKTORY Umbrella Trial.

Lee J, Kim ST, Kim K, Lee H, Kozarewa I, Mortimer PG, Odegaard JI, Harrington EA, Lee J, Lee T, Oh SY, Kang JH, Kim JH, Kim Y, Ji JH, Kim YS, Lee KE, Kim J, Sohn TS, An JY, Choi MG, Lee JH, Bae JM, Kim S, Kim JJ, Min YW, Min BH, Kim NKD, Luke S, Kim YH, Hong JY, Park SH, Park JO, Park YS, Lim HY, Talasaz A, Hollingsworth SJ, Kim KM, Kang WK.

Cancer Discov. 2019 Jul 17. pii: CD-19-0442. doi: 10.1158/2159-8290.CD-19-0442. [Epub ahead of print]

PMID:
31315834
6.

High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer.

Kim Y, Byeon SJ, Hur J, Lee K, Kim D, Ahn JH, Lee SH, You WK, Kim ST, Park SH, Kang WK, Kim KM, Lee J.

J Cancer. 2019 Jun 2;10(14):3172-3178. doi: 10.7150/jca.30257. eCollection 2019.

7.

The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.

Yoon SE, Kim JH, Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST.

J Cancer. 2019 Jun 2;10(14):3140-3144. doi: 10.7150/jca.30355. eCollection 2019.

8.

LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target.

Lee SJ, Byeon SJ, Lee J, Park SH, Park JO, Park YS, Kang WK, Lim HY, Kim KM, Kim ST.

J Immunother. 2019 Oct;42(8):279-283. doi: 10.1097/CJI.0000000000000283.

PMID:
31219974
9.

The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer.

Yoon SE, Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST.

J Cancer. 2019 Mar 3;10(7):1611-1615. doi: 10.7150/jca.29106. eCollection 2019.

10.

Safety of Laparoscopic Oncologic Resection in Elderly Patients with Colorectal Cancer: A Multicenter Retrospective Study Based on Perioperative Short-Term Outcomes.

Kye BH, Rookkachart T, Kim JH, Kim HJ, Lee YS, Lee IK, Kang WK, Cho HM, Oh ST.

J Laparoendosc Adv Surg Tech A. 2019 Aug;29(8):1016-1022. doi: 10.1089/lap.2019.0049. Epub 2019 Jun 12.

PMID:
31188061
11.

CCNE1 amplification is associated with liver metastasis in gastric carcinoma.

Kim B, Shin HC, Heo YJ, Ha SY, Jang KT, Kim ST, Kang WK, Lee J, Kim KM.

Pathol Res Pract. 2019 Aug;215(8):152434. doi: 10.1016/j.prp.2019.152434. Epub 2019 May 4.

PMID:
31178228
12.

Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial.

Miceli R, An J, Di Bartolomeo M, Morano F, Kim ST, Park SH, Choi MG, Lee JH, Raimondi A, Fucà G, Sohn TS, Bae JM, Kim S, Lim DH, Kang WK, Kim KM, Pietrantonio F, Lee J.

Oncology. 2019;97(1):38-43. doi: 10.1159/000499628. Epub 2019 May 2.

PMID:
31048579
13.

Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing: A Direct Comparison Study with Immunohistochemistry.

Choi S, Chu J, Kim B, Ha SY, Kim ST, Lee J, Kang WK, Han H, Sohn I, Kim KM.

J Mol Diagn. 2019 Jul;21(4):612-622. doi: 10.1016/j.jmoldx.2019.02.007. Epub 2019 Apr 22.

PMID:
31022472
14.

Bridging genomics and phenomics of gastric carcinoma.

Cho J, Ahn S, Son DS, Kim NK, Lee KW, Kim S, Lee J, Park SH, Park JO, Kang WK, An JY, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Kim KM.

Int J Cancer. 2019 Nov 1;145(9):2407-2417. doi: 10.1002/ijc.32228. Epub 2019 Mar 18.

PMID:
30801717
15.

PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer.

Angell HK, Lee J, Kim KM, Kim K, Kim ST, Park SH, Kang WK, Sharpe A, Ogden J, Davenport A, Hodgson DR, Barrett JC, Kilgour E.

Oncoimmunology. 2018 Dec 10;8(2):e1544442. doi: 10.1080/2162402X.2018.1544442. eCollection 2019.

16.

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial.

Kim ST, Lee S, Park M, Park SH, Park JO, Lim HY, Park YS, Kang WK, Gangolli EA, Shin H, Kim KM, Hollingsworth SJ, Mortimer PGS, Lee J.

Transl Oncol. 2019 Apr;12(4):597-601. doi: 10.1016/j.tranon.2018.12.009. Epub 2019 Jan 26.

17.

Deep Learning-Based Survival Analysis Identified Associations Between Molecular Subtype and Optimal Adjuvant Treatment of Patients With Gastric Cancer.

Lee J, An JY, Choi MG, Park SH, Kim ST, Lee JH, Sohn TS, Bae JM, Kim S, Lee H, Min BH, Kim JJ, Jeong WK, Choi DI, Kim KM, Kang WK, Kim M, Seo SW.

JCO Clin Cancer Inform. 2018 Dec;2:1-14. doi: 10.1200/CCI.17.00065.

18.

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice.

Yoon SE, Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST.

Onco Targets Ther. 2018 Dec 24;12:225-231. doi: 10.2147/OTT.S187621. eCollection 2019.

19.

Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer.

Sundar R, Huang KK, Qamra A, Kim KM, Kim ST, Kang WK, Tan ALK, Lee J, Tan P.

Ann Oncol. 2019 Mar 1;30(3):424-430. doi: 10.1093/annonc/mdy550.

20.

Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial.

Kim Y, Kim KM, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Lee SJ, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH.

J Gastric Cancer. 2018 Dec;18(4):348-355. doi: 10.5230/jgc.2018.18.e34. Epub 2018 Nov 16.

21.

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).

Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M, Chen LT, Kang YK.

Ann Oncol. 2019 Feb 1;30(2):250-258. doi: 10.1093/annonc/mdy540.

22.

Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer.

Oh SY, Lee S, Huh SJ, Lee J, Kim ST, Park SH, Lim HY, Kang WK, Kang BW, Kim JG, Lee HJ, Kim JH, Kang JH, Kim H.

Cancer Chemother Pharmacol. 2019 Mar;83(3):501-508. doi: 10.1007/s00280-018-3753-y. Epub 2018 Dec 8.

PMID:
30535535
23.

A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.

Kim Y, Kim TW, Han SW, Ahn JB, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK.

Cancer Res Treat. 2019 Jul;51(3):1128-1134. doi: 10.4143/crt.2018.379. Epub 2018 Nov 21.

24.

The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma.

Cho J, Kim KM, Kim HC, Lee WY, Kang WK, Park YS, Ha SY.

Pathol Res Pract. 2019 Jan;215(1):171-176. doi: 10.1016/j.prp.2018.10.024. Epub 2018 Oct 24.

PMID:
30466765
25.

MET is overexpressed in microsatellite instability-high gastric carcinoma.

Sim J, Heo YJ, Bae H, Shin HC, Kim B, Cho J, Kim ST, Lee J, Kang WK, Kim KM.

Pathol Res Pract. 2019 Mar;215(3):433-438. doi: 10.1016/j.prp.2018.11.010. Epub 2018 Nov 12.

PMID:
30455128
26.

Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line.

Kim ST, Kim SY, Lee J, Kim K, Park SH, Park YS, Lim HY, Kang WK, Park JO.

BMC Cancer. 2018 Nov 12;18(1):1103. doi: 10.1186/s12885-018-4995-0.

27.

Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols.

Yu JI, Lim DH, Lee J, Kang WK, Park SH, Park JO, Park YS, Lim HY, Kim ST, Lee SJ, Kim S, Sohn TS, Lee JH, An JY, Choi MG, Bae JM, Yoo H, Kim K.

Cancer Res Treat. 2019 Jul;51(3):876-885. doi: 10.4143/crt.2018.401. Epub 2018 Oct 1.

28.

Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation.

Lee T, Kim K, Lee J, Park SH, Park YS, Lim HY, Kang WK, Park JO, Kim ST.

J Cancer. 2018 Sep 8;9(18):3394-3399. doi: 10.7150/jca.26068. eCollection 2018.

29.

Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial.

Lim SW, Lee S, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST.

J Cancer. 2018 Jul 30;9(16):2910-2915. doi: 10.7150/jca.24948. eCollection 2018.

30.

Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer.

Yu JI, Lim DH, Lee J, Kang WK, Park SH, Park JO, Park YS, Lim HY, Kim ST, Lee SJ, Kim S, Sohn TS, Lee JH, An JY, Choi MG, Bae JM, Kim HS, Ahn S.

Radiother Oncol. 2018 Nov;129(2):306-312. doi: 10.1016/j.radonc.2018.07.002. Epub 2018 Jul 20.

PMID:
30037498
31.

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.

Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M, Lee S, Park SH, Park JO, Park YS, Lim HY, Lee H, Choi M, Talasaz A, Kang PS, Cheng J, Loboda A, Lee J, Kang WK.

Nat Med. 2018 Sep;24(9):1449-1458. doi: 10.1038/s41591-018-0101-z. Epub 2018 Jul 16.

PMID:
30013197
32.

The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer.

Kim ST, Kim HK, Lee J, Park SH, Lim HY, Park YS, Kang WK, Park JO.

J Cancer. 2018 Apr 19;9(10):1791-1796. doi: 10.7150/jca.25132. eCollection 2018.

33.

Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype.

Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim SC, Heo J, Chu IS, Jang YJ, Mok YJ, Jung W, Kim BH, Kim A, Cho JY, Lim JY, Hayashi Y, Song S, Elimova E, Estralla JS, Lee JH, Bhutani MS, Lu Y, Liu W, Lee J, Kang WK, Kim S, Noh SH, Mills GB, Kim SY, Ajani JA, Lee JS.

Nat Commun. 2018 May 3;9(1):1777. doi: 10.1038/s41467-018-04179-8.

34.

Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability.

Cho J, Chang YH, Heo YJ, Kim S, Kim NK, Park JO, Kang WK, Lee J, Kim KM.

ESMO Open. 2018 Mar 15;3(3):e000326. doi: 10.1136/esmoopen-2018-000326. eCollection 2018.

35.

c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival.

Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST.

Clin Colorectal Cancer. 2018 Sep;17(3):165-169. doi: 10.1016/j.clcc.2018.02.013. Epub 2018 Mar 2.

36.

Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer.

Lee J, Kim ST, Park S, Lee S, Park SH, Park JO, Lim HY, Ahn H, Bok H, Kim KM, Ahn MJ, Kang WK, Park YS.

Clin Colorectal Cancer. 2018 Jun;17(2):140-146. doi: 10.1016/j.clcc.2018.01.005. Epub 2018 Jan 31.

PMID:
29551559
37.
38.

Analysis of lawsuit cases in the Department of Surgery in Korea.

Jung JY, Kim SY, Kim DG, Kim CB, Chi KC, Kang WK, Lee W.

Ann Surg Treat Res. 2018 Mar;94(3):113-117. doi: 10.4174/astr.2018.94.3.113. Epub 2018 Feb 28.

39.

MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis.

Kim HK, Lee I, Bang H, Kim HC, Lee WY, Yun SH, Lee J, Lee SJ, Park YS, Kim KM, Kang WK.

Mol Cancer Ther. 2018 Apr;17(4):838-848. doi: 10.1158/1535-7163.MCT-17-0535. Epub 2018 Feb 26.

40.

The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer.

Lee SJ, Kim JE, Kim ST, Lee J, Park SH, Park JO, Kang WK, Park YS, Lim HY.

Transl Oncol. 2018 Apr;11(2):353-357. doi: 10.1016/j.tranon.2018.01.007. Epub 2018 Feb 20.

41.

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients.

Kim ST, Banks KC, Pectasides E, Kim SY, Kim K, Lanman RB, Talasaz A, An J, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Park SH, Park JO, Park YS, Lim HY, Kim NKD, Park W, Lee H, Bass AJ, Kim K, Kang WK, Lee J.

Ann Oncol. 2018 Apr 1;29(4):1037-1048. doi: 10.1093/annonc/mdy034.

42.

Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11.

Kim HS, Ryu MH, Zang DY, Park SR, Han B, Kang WK, Rha SY, Jung M, Kim JS, Kang BW, Lee KH, Rho SY, Kim JH, Kim KC, Cho JW, Choi DR, Lim H, Kang HS, Soh JS, Kim MJ, Seo J, Kang YK.

Gastric Cancer. 2018 Sep;21(5):802-810. doi: 10.1007/s10120-018-0794-1. Epub 2018 Jan 25.

PMID:
29372461
43.

Correlation between MEK signature and Ras gene alteration in advanced gastric cancer.

Ahn S, Brant R, Sharpe A, Dry JR, Hodgson DR, Kilgour E, Kim K, Kim ST, Park SH, Kang WK, Kim KM, Lee J.

Oncotarget. 2017 May 23;8(64):107492-107499. doi: 10.18632/oncotarget.18182. eCollection 2017 Dec 8.

44.

Elevated CEA is associated with worse survival in recurrent rectal cancer.

Cho WK, Choi DH, Park HC, Park W, Yu JI, Park YS, Park JO, Lim HY, Kang WK, Kim HC, Cho YB, Yun SH, Lee WY.

Oncotarget. 2017 Nov 18;8(62):105936-105941. doi: 10.18632/oncotarget.22511. eCollection 2017 Dec 1.

45.

MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines.

Kim JE, Kim Y, Li G, Kim ST, Kim K, Park SH, Park JO, Park YS, Lim HY, Lee H, Sohn TS, Kim KM, Kang WK, Lee J.

Oncotarget. 2017 Nov 11;8(62):105727-105734. doi: 10.18632/oncotarget.22394. eCollection 2017 Dec 1.

46.

Protective Effects of Female Reproductive Factors on Lauren Intestinal-Type Gastric Adenocarcinoma.

Kim SM, Min BH, Lee J, An JY, Lee JH, Sohn TS, Bae JM, Kim JJ, Kang WK, Kim S, Choi MG.

Yonsei Med J. 2018 Jan;59(1):28-34. doi: 10.3349/ymj.2018.59.1.28.

47.

Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity.

Park C, Cho J, Lee J, Kang SY, An JY, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Kim ST, Park SH, Park JO, Kang WK, Sohn I, Jung SH, Kang MS, Kim KM.

Oncoimmunology. 2017 Aug 10;6(11):e1356150. doi: 10.1080/2162402X.2017.1356150. eCollection 2017.

48.

Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy.

Kim ST, Klempner SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim KM, Lee J.

Oncotarget. 2017 Aug 24;8(44):77415-77423. doi: 10.18632/oncotarget.20492. eCollection 2017 Sep 29.

49.

The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs.

Kim HK, Ha SY, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST.

Oncotarget. 2017 May 25;8(43):73974-73980. doi: 10.18632/oncotarget.18168. eCollection 2017 Sep 26.

50.

Development of mesenchymal subtype gene signature for clinical application in gastric cancer.

Lee J, Cristescu R, Kim KM, Kim K, Kim ST, Park SH, Kang WK.

Oncotarget. 2017 Aug 7;8(39):66305-66315. doi: 10.18632/oncotarget.19985. eCollection 2017 Sep 12.

Supplemental Content

Support Center